Journal of Clinical Oncology, Vol 16, 1490-1493, Copyright © 1998 by American Society of Clinical Oncology

ARTICLES

Morbidity and mortality after D2 gastrectomy for gastric cancer: results of the Italian Gastric Cancer Study Group prospective multicenter surgical study

M Degiuli, M Sasako, A Ponti, T Soldati, F Danese and F Calvo
Department of Oncology, Turin, Italy.

PURPOSE: To investigate whether pancreas preservation together with a strict quality-control system could ameliorate the outcome of D2 resections for gastric cancer in Western patients. PATIENTS AND METHODS: Italian patients with potentially curable proven adenocarcinoma of the stomach were registered from nine general and/or university hospitals in the area of Turin, Northern Italy. The study was performed according to the guidelines of the Japanese Research Society for Gastric Cancer (JRSGC). A strict quality-control system was guaranteed by a supervising surgeon of the reference center, who had stayed at the National Cancer Center Hospital, Tokyo, to learn the standard D2 gastrectomy. The standard procedure entailed removal of the level 1 and 2 lymph nodes. During total gastrectomy, the pancreas was preserved according to the Maruyama technique. RESULTS: Between May 1994 and December 1996, 191 eligible patients were entered onto the study. The mean number of lymph nodes removed was 39. The overall morbidity rate was 20.9%. Surgical complications were observed in 16.7% of patients. Reoperation was necessary in six patients and was always successful. The overall hospital mortality rate was 3.1%; it was higher after total gastrectomy (7.46%) than after distal gastrectomy (0.8%). The average length of hospital stay was 17 days. CONCLUSION: Given that postoperative morbidity and mortality rates are favorably comparable with those reported after the Western standard gastrectomy, the more extensive Japanese procedure with pancreas preservation can be regarded as a safe radical treatment of gastric cancer for selected Western patients treated in experienced centers.
CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				S. S. Yoon and H.-K. Yang Lymphadenectomy for Gastric Adenocarcinoma: Should West Meet East? Oncologist, September 1, 2009; 14(9): 871 - 882. [Abstract] [Full Text] [PDF]

				F. Di Costanzo, S. Gasperoni, L. Manzione, G. Bisagni, R. Labianca, S. Bravi, E. Cortesi, P. Carlini, R. Bracci, S. Tomao, et al. Adjuvant Chemotherapy in Completely Resected Gastric Cancer: A Randomized Phase III Trial Conducted by GOIRC J Natl Cancer Inst, March 19, 2008; 100(6): 388 - 398. [Abstract] [Full Text] [PDF]

				R. E. Schwarz and D. D. Smith Extended Lymph Node Dissection for Gastric Cancer: Who May Benefit? Final Results of the Randomized Dutch Gastric Cancer Group Trial J. Clin. Oncol., August 10, 2005; 23(23): 5404 - 5405. [Full Text] [PDF]

				T. Sano, M. Sasako, S. Yamamoto, A. Nashimoto, A. Kurita, M. Hiratsuka, T. Tsujinaka, T. Kinoshita, K. Arai, Y. Yamamura, et al. Gastric Cancer Surgery: Morbidity and Mortality Results From a Prospective Randomized Controlled Trial Comparing D2 and Extended Para-Aortic Lymphadenectomy--Japan Clinical Oncology Group Study 9501 J. Clin. Oncol., July 15, 2004; 22(14): 2767 - 2773. [Abstract] [Full Text] [PDF]

				K.C.M.J. Peeters and C.J.H. van de Velde Improving Treatment Outcome for Gastric Cancer: The Role of Surgery and Adjuvant Therapy J. Clin. Oncol., December 1, 2003; 21(90230): 272s - 273. [Full Text] [PDF]

				M. Sasako Principles of Surgical Treatment for Curable Gastric Cancer J. Clin. Oncol., December 1, 2003; 21(90230): 274s - 275. [Full Text] [PDF]